amlodipine + olmesartan + rosuvastatin + ezetimibe

Amlodipine + olmesartan + rosuvastatin + ezetimibe is a combination drug consisting of four small molecule agents used for the management of cardiovascular risk factors, specifically hypertension and dyslipidemia. - **Amlodipine** is a calcium channel blocker that inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle, causing vasodilation and a reduction in blood pressure. - **Olmesartan** is an angiotensin II receptor blocker (ARB) that inhibits the vasoconstrictor and aldosterone-secreting actions of angiotensin II by selectively blocking its binding to the AT1 receptor in vascular smooth muscle. - **Rosuvastatin** is a statin that inhibits HMG-CoA reductase, reducing cholesterol synthesis in the liver, resulting in lowered low-density lipoprotein cholesterol (LDL-C) and total cholesterol. - **Ezetimibe** inhibits the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing the absorption of cholesterol. The combination is intended for use in adults with concurrent hypertension and dyslipidemia, aiming to simplify medication regimens, improve adherence, and maximize cardiovascular benefit[2].